NCT04526197View on ClinicalTrials.gov

Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 7, 2020

Primary Completion Date

November 3, 2020

Study Completion Date

November 3, 2020

Conditions
Wilson Disease
Interventions
DRUG

ALXN1840

ALXN1840 was administered orally as a single dose as 4 x 15 milligram (mg) enteric-coated tablets with 240 milliliters (mL) of water (fasting), for a total dose of 60 mg.

DRUG

Celecoxib

Celecoxib was administered orally as a single dose as one 200-mg tablet with 240 mL of water (fasting).

Trial Locations (1)

78744

Clinical Trial Site, Austin

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY